TARS Earnings

Quarterly EPS
$-0.61
Q3 2024
$-0.59
Q4 2024
$-0.64
Q1 2025
$-0.48
Q2 2025
$-0.30
Q3 2025
$-0.19
Q4 2025
$-0.16
Q1 2026
$-0.43
Q2 2026
Latest Revenue173.9M
Latest Net Income-18551000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.43173.9M-18551000+69.4%+10.4%
Q1 2026-$0.16162.1M-6967000+106.9%+75.0%
Q4 2025-$0.19151.7M-8373000+128.4%+67.8%
Q3 2025-$0.30118.7M-12585000+146.7%+50.8%
Q2 2025-$0.48102.7M-20340000+151.5%+45.5%
Q1 2025-$0.6478.3M-25120000+183.7%+36.6%
Q4 2024-$0.5966.4M-23113000+407.9%+53.2%
Q3 2024-$0.6148.1M-23420000+2,471.8%+52.3%
Q2 2024-$0.8840.8M-33290000
Q1 2024-$1.0127.6M-35731000
Q4 2023-$1.2613.1M-41902000
Q3 2023-$1.281.9M-39148000
Tarsus Pharmaceuticals (TARS) — Earnings